Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation

Nicholas S Downing¹, Harlan M Krumholz^{1

2}, Joseph S Ross^{1

2}, Nilay D Shah³

Affiliations

¹ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA.
² Yale University School of Medicine, P.O. Box 208093, New Haven, Connecticut 06520, USA.
³ Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota.

Nicholas S Downing et al. Nat Rev Drug Discov. 2015 Nov.

. 2015 Nov;14(11):740-1.

doi: 10.1038/nrd4734. Epub 2015 Oct 5.

Nicholas S Downing¹, Harlan M Krumholz^{1

2}, Joseph S Ross^{1

2}, Nilay D Shah³

¹ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA.
² Yale University School of Medicine, P.O. Box 208093, New Haven, Connecticut 06520, USA.
³ Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota.

No abstract available

MeSH terms